US Stock MarketDetailed Quotes

DMAA Drugs Made In America Acquisition Corp

Watchlist
  • 10.020
  • -0.040-0.40%
Close Apr 4 16:00 ET
  • 10.750
  • +0.730+7.29%
Post 20:01 ET
335.84MMarket Cap0.00P/E (TTM)

Drugs Made In America Acquisition Corp Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
Assets
Current assets
Cash, cash equivalents and short term investments
--1.35K
--2.1K
--18.1K
-Cash and cash equivalents
--1.35K
--2.1K
--18.1K
Prepaid assets
--3.64K
--0
--60K
Total current assets
--4.99K
--2.1K
--78.1K
Non current assets
Non current deferred assets
--545.83K
--424.04K
--112.96K
Total non current assets
--545.83K
--424.04K
--112.96K
Total assets
--550.82K
--426.14K
--191.06K
Liabilities
Current liabilities
Current accrued expenses
--133.35K
--38.98K
--896
Current debt and capital lease obligation
--662.32K
--552.02K
--210.09K
-Current debt
--662.32K
--552.02K
--210.09K
Current liabilities
--795.67K
--591K
--210.99K
Non current liabilities
Total non current liabilities
--0
--0
--0
Total liabilities
--795.67K
--591K
--210.99K
Shareholders'equity
Share capital
--986
--986
--2.24K
-common stock
--986
--986
--2.24K
-Preferred stock
--0
--0
--0
Retained earnings
---279.85K
---199.86K
---54.93K
Paid-in capital
--34.01K
--34.01K
--32.76K
Total stockholders'equity
---244.85K
---164.86K
---19.93K
Total equity
---244.85K
---164.86K
---19.93K
Currency Unit
USD
USD
USD
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
(FY)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024
Assets
Current assets
Cash, cash equivalents and short term investments --1.35K--2.1K--18.1K
-Cash and cash equivalents --1.35K--2.1K--18.1K
Prepaid assets --3.64K--0--60K
Total current assets --4.99K--2.1K--78.1K
Non current assets
Non current deferred assets --545.83K--424.04K--112.96K
Total non current assets --545.83K--424.04K--112.96K
Total assets --550.82K--426.14K--191.06K
Liabilities
Current liabilities
Current accrued expenses --133.35K--38.98K--896
Current debt and capital lease obligation --662.32K--552.02K--210.09K
-Current debt --662.32K--552.02K--210.09K
Current liabilities --795.67K--591K--210.99K
Non current liabilities
Total non current liabilities --0--0--0
Total liabilities --795.67K--591K--210.99K
Shareholders'equity
Share capital --986--986--2.24K
-common stock --986--986--2.24K
-Preferred stock --0--0--0
Retained earnings ---279.85K---199.86K---54.93K
Paid-in capital --34.01K--34.01K--32.76K
Total stockholders'equity ---244.85K---164.86K---19.93K
Total equity ---244.85K---164.86K---19.93K
Currency Unit USDUSDUSD
Audit Opinions Unqualified Opinion with Explanatory Notes----

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
WINSUNBIO
839729
+29.98%
HIGO
872351
+29.93%
DRIVE
838275
+20.30%
4
Shanghai Menon Animal Nutrition Technology
301156
+20.03%
5
Nanjing Railway New Technology
301016
+20.02%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Trump's comeback to the Office

Following Trump's Policies to Seek Investment Opportunities

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call